Carlos López

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.3K citations · Full text

Hepatology, Medicine, Randomised Phase 3 +11

High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non–small-cell lung cancer: Long-term results of a radiation dose escalation study

Feng‐Ming Kong, Randall K. Ten Haken, Matthew J. Schipper et al. · International Journal of Radiation Oncology*Biology*Physics · 2005 · 495 citations

Adaptive Radiotherapy, Radiation Medicine, High-dose Radiation +9

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Lorenza Rimassa, Eric Assénat, Markus Peck‐Radosavljevic et al. · The Lancet Oncology · 2018 · 340 citations

Second-line Treatment, Hepatology, Medicine +10

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 254 citations · Full text